A Multiple Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACH-0144471 in Healthy Volunteers

Trial Profile

A Multiple Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACH-0144471 in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 18 May 2017

At a glance

  • Drugs ACH 4471 (Primary)
  • Indications Paroxysmal nocturnal haemoglobinuria
  • Focus Adverse reactions
  • Sponsors Achillion Pharmaceuticals
  • Most Recent Events

    • 15 May 2017 Status changed from recruiting to completed.
    • 14 Jun 2016 Status changed from planning to not yet recruiting.
    • 14 Jun 2016 New source identified and integrated (Australian New Zealand Clinical Trials Registry; ACTRN12616000568415p).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top